| Document |
Document Title |
|
WO/2022/255384A1 |
Provided is a pharmaceutical composition which can exhibit an anti-tumor effect more potently, more efficiently, more sustainably, and/or in a wider range. A composition comprising a hyaluronic acid derivative having a hydrophobic group ...
|
|
WO/2022/255282A1 |
The present invention provides: a dynamic visual acuity-enhancing composition comprising eugenol as an active ingredient; a composition for suppressing reductions in dynamic visual acuity in the elderly, said composition comprising, as a...
|
|
WO/2022/255346A1 |
The purpose of the present invention is to provide a method for treating or preventing a disease or the like which pertains to mitochondrial function by using a substance which pertains to the decline or improvement of mitochondrial func...
|
|
WO/2022/255955A1 |
The present invention relates to ((1S,9S)-11-{[4-(1,3-benzodioxol-5-ylamino)-8-methyl-2-quina
zolinyl]methyl}-7,11-diazatricyclo[7.3.1.0~2,7~] trideca-2,4-dien-6-one) compound and related derivatives. The compound of the invention is a C...
|
|
WO/2022/255790A1 |
The present disclosure relates to medical use of a compound of chemical formula 1 for treatment or prevention of pulmonary fibrosis. The present disclosure also relates to combination therapy with the compound of chemical formula 1 and n...
|
|
WO/2022/255276A1 |
The purpose of the present invention is to provide a composition for improving or suppressing decline of social healthiness and a method for improving or suppressing decline of social healthiness. The present invention pertains to a comp...
|
|
WO/2022/255248A1 |
The purpose of the present disclosure is to develop a new combination therapy that exerts a superior antitumor effect as compared to administration of an anti-CD26 antibody alone. In order to assess both the function of an immune checkpo...
|
|
WO/2022/256379A1 |
Provided herein are pharmaceutical compositions, kits comprising pharmaceutical compositions, methods of treating disease, and methods of making compositions and kits described herein. The pharmaceutical compositions described herein are...
|
|
WO/2022/250085A1 |
A new target molecule for pruritis has been discovered, and a novel means for eliminating pruritis is provided. This agent for preventing or ameliorating intractable pruritis uses a C3a receptor antagonist as an active ingredient.
|
|
WO/2022/248835A1 |
The present invention relates to methods for increasing the anti-tumor immune response in a patient suffering from cancer, a method for the treatment or prophylaxis of cancer, and a method for enhancing the effectiveness of an inhibitor ...
|
|
WO/2022/250027A1 |
This anti-inflammatory agent for the intestinal cells of a non-human animal is characterized by containing cashew nut shell oil, heat-treated cashew nut shell oil, anacardic acid, cardanol and/or cardol, and vitamin K.
|
|
WO/2022/251386A1 |
A method of treatment is disclosed. The method comprises administering to a human subject having or at risk of developing a disease associated with decreased expression of one or more genes encoding cytochrome P450, an effective amount o...
|
|
WO/2022/250072A1 |
The present invention provides a therapeutic agent for cardiac disease that includes an oligonucleotide having one or more nucleotides represented by formula I or formula II below: (in formulas I and II: Base represents a 2-oxo-1, 2-dihy...
|
|
WO/2022/250050A1 |
Provided is a double-stranded nucleic acid complex that exhibits a reduced toxicity without a loss of effectiveness. Provided is a double-stranded nucleic acid complex, comprising a first nucleic acid strand and a second nucleic acid s...
|
|
WO/2022/251304A1 |
The present invention provides compounds (I) useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
|
|
WO/2022/251302A1 |
The present invention provides compounds useful as orexin-2 receptor agonists for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
|
|
WO/2022/251812A1 |
Provided herein are methods of treating a movement disorder in an individual in need thereof, comprising administering to the individual an oral dosage form of CX-8998 or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/250070A1 |
The purpose of the present invention is to provide a more effective treatment method for cancer treatment that utilizes the tumor immune system. A further purpose of the present invention is to provide, as a more effective tumor immunoth...
|
|
WO/2022/250108A1 |
The present invention pertains to a therapeutic agent or preventative agent against diseases involving an orexin receptor, particularly an orexin type-2 receptor, the agent containing a novel compound having a urea skeleton, or a pharmac...
|
|
WO/2022/250155A1 |
An oligonucleotide, which expresses a functional human WRN protein for exon 26 or exon 28 skipping mutation in human WRN gene, or a pharmaceutically acceptable salt thereof, wherein: the individual nucleotides in the oligonucleotide are ...
|
|
WO/2022/244727A1 |
The present disclosure provides a composition for improving cognitive function that comprises a fish roe lipid preparation. In one embodiment, provided is a composition for improving cognitive function that comprises a fish roe lipid pre...
|
|
WO/2022/246195A1 |
Provided herein are functional moieties, functionalized compounds and macromolecules, their preparation, and uses thereof.
|
|
WO/2022/242581A1 |
Provided herein are compounds of Formula Ia and Ib, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, including those mediated by receptor-interacting protein 1 (R...
|
|
WO/2022/246039A1 |
Disclosed herein are methods of treatment comprising administering a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole
or a pharmaceutically acceptable salt thereof to a subject in need the...
|
|
WO/2022/244447A1 |
The present invention addresses the problem of providing: (1) a composition that is for inhibiting differentiation of osteoclast precursor cells into osteoclasts, improving bone metabolism, and/or inhibiting a reduction in bone density, ...
|
|
WO/2022/243973A1 |
The use of 2,4-disubstituted thiadiazolidinone (TDZD) compounds, such as Tideglusib (4-Benzyl-2-naphthalen-1-yl-[1,2,4]thiadiazolidine-3,5-dione
), in methods of inhibiting RNA molecules comprising abnormal trinucleotide repeats (such as...
|
|
WO/2022/244854A1 |
The present invention addresses the problem of providing: an antibody which can bind to CD206 and can remove a CD206-positive M2 macrophage in an adipose tissue; an agent for killing a CD206-positive M2 macrophage cell; and a pharmaceuti...
|
|
WO/2022/243651A1 |
The present invention relates to compounds of formula (I): for use in the prevention and/or treatment of cancer, autoimmune and inflammatory diseases, graft rejection and fibroses.
|
|
WO/2022/244867A1 |
The present invention relates to a composition for improving cognitive function, which contains glycine and serine, in which the weight ratio of the content of glycine to the content of serine, i.e., (glycine/serine), is 0.6 or more. A...
|
|
WO/2022/244580A1 |
Provided is an immunostimulator that contains β-glucan derived from yeast cell walls and that has a high immunostimulation effect. This immunostimulator contains β-glucan derived from yeast cell walls, and the percentage content of sai...
|
|
WO/2022/243435A1 |
The present invention relates to i) KL1333 for use in the treatment of mitochondrial diseases or diseases associated with mitochodrial diseases such as fatigue such as fatigue syndrome and fatigue associated with a disease or muscle weak...
|
|
WO/2022/243574A1 |
The present invention provides 3-(phthalazin-1-yl)benzenesulfonamide-based compounds of formula (I), Formula (I) and pharmaceutically acceptable salts thereof, which have been found to be advantageously potent and selective inhibitors of...
|
|
WO/2022/243683A1 |
A composition comprising at least one phyllosilicate mineral for use in the prevention and/or treatment of mycotoxic disease caused by sporidesmin and in particular for use in the prevention and or/treatment of pithomycotoxosis.
|
|
WO/2022/244852A1 |
The present invention addresses the problem of clarifying the relationship between the onset and progression of cancer and macrophages and providing a novel pharmaceutical composition for preventing or treating cancer. The present invent...
|
|
WO/2022/242692A1 |
Provided is use of an antibody-drug conjugate targeting Her2 in combination with an immune checkpoint inhibitor such as PD-1 antibody or PD-L1 antibody, in the preparation of a medicine for treating patients with urothelial cancer, espec...
|
|
WO/2022/244891A1 |
An antigen peptide which contains at least five continuous amino acid residues contained in the amino acid sequence represented by SEQ ID NO: 52, has an activity of inducing a cytotoxic T cell and/or a helper T cell, and can induce the c...
|
|
WO/2022/244846A1 |
The present invention provides a composition for regulating cell proliferation, said composition containing a regulator of D-amino acid content, or a composition that activates an mTOR-related pathway. The present invention also provides...
|
|
WO/2022/244915A1 |
The present invention relates to a composition comprising a euscaphic acid, and the use thereof for relieving fatigue and, more specifically, to a food composition, a health functional food composition, and/or a pharmaceutical compositio...
|
|
WO/2022/244692A1 |
The purpose of the present invention is to provide: a composition that contains 1'-acetoxychavicol acetate and that can enhance the anti-inflammatory action of 1'-acetoxychavicol acetate; and a method for preventing inflammation or for i...
|
|
WO/2022/246200A1 |
Methods of treating proteinuric glomerular diseases are provided, including methods comprising administering a compound having structure (I), or a pharmaceutically acceptable salt thereof, to a subject in need thereof. In some embodiment...
|
|
WO/2022/244876A1 |
The purpose of the present invention is to provide a new antitumor agent. Specifically, the present invention uses, as an antitumor agent, T-cells expressing a T-cell receptor including a peptide represented by SEQ ID NO: 1 and a peptide...
|
|
WO/2022/237878A1 |
Disclosed in the present invention are a crystal form of a compound, a composition containing the crystal form, a preparation method therefor and the use thereof. The crystal forms, i.e. crystal form I and crystal form II, of a compound ...
|
|
WO/2022/240035A1 |
A pharmaceutical composition according to the present invention is used in a specific therapeutic dosage regimen, and can be effectively used for the prevention or treatment of fibrosis.
|
|
WO/2022/240036A1 |
The present invention relates to a pharmaceutical composition that can be usefully used for the prevention or treatment of fibrosis. By using a first component and a second component together according to the present invention, the preve...
|
|
WO/2022/239715A1 |
[Problem] The purpose of the present invention is to provide formulation technology with which it is possible to suppress browning that occurs over time in a topical composition containing a non-steroidal anti-inflammatory, 0.015 wt% or ...
|
|
WO/2022/240116A1 |
The present invention provides a novel compound having an inhibitory activity against glucosylceramide synthase (GCS), i.e., compounds having a 2,3-dihydro-1H-indene, 1,2,3,4-tetrahydronaphthalene, or chromane moiety, or pharmaceutically...
|
|
WO/2022/238400A1 |
The present invention relates to a composition comprising: - at least one molecule covalently conjugated to a polylysine, and - at least one hydrophobic molecule which cannot be covalently conjugated to a polylysine, said molecule being ...
|
|
WO/2022/239068A1 |
The present invention relates to a novel cytokine storm inhibitor containing, as an active ingredient, a compound represented by general formula [1]: [in the formula, R1 R2, R3, R4, R5, and X are as defined in the description], or a phar...
|
|
WO/2022/239735A1 |
Provided is an industrially applicable apixaban purification method whereby high removability of analogous substances and a good re-crystallization yield are achieved. This apixaban purification method is characterized in that a base is ...
|
|
WO/2022/239870A1 |
A composition containing blood-derived growth factor more effective against wound healing and tissue regeneration, and a preparation method of said composition containing blood-derived growth factor are provided. One embodiment is a meth...
|
